BOSTON–(BUSINESS WIRE)–PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology firm advancing the subsequent era of oligonucleotide therapies with the aim of reworking the therapy of extreme neuromuscular and neurological ailments, immediately introduced the appointment of Paul Streck, M.D., MBA, as Govt Vice President, Head of Analysis & Growth (R&D), efficient instantly. Dr. Streck will be a part of the PepGen Govt Group and will probably be answerable for main the R&D group.
We’re very happy that Paul is becoming a member of PepGen at such an essential time for the Firm, stated James McArthur, Ph.D., President and CEO of PepGen. All through his profession, Paul has served in management roles throughout each massive and small publicly traded biopharmaceutical firms, with notable accomplishments together with 5 IND approvals, six international regulatory launches, and 9 business product launches. This breadth of expertise has geared up him with institutional data that will probably be of maximum worth to PepGen as we proceed to advance our 4 lively medical trials and rising pipeline of preclinical candidates.
Dr. Streck has greater than 20 years of expertise in drug growth, regulatory, and medical affairs management. Most just lately, he served as Chief Medical Officer at Albireo Pharma (NASDAQ:), a publicly traded uncommon illness biotechnology firm acquired by Ipsen in March 2023. Beforehand, Dr. Streck was Chief Medical Officer at Area Prescription drugs, a publicly traded immuno-inflammatory biotechnology firm acquired by Pfizer (NYSE:) in March 2022. Earlier than that, he served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Prescription drugs in October 2020, and because the Chief Medical Officer of Insmed (NASDAQ:), advancing the corporate from medical to business stage. Earlier biopharmaceutical expertise contains progressive roles at GSK, Shire, and Amgen (NASDAQ:), in addition to 10 years in tutorial medical follow.
About PepGen
PepGen Inc. is a clinical-stage biotechnology firm advancing the next-generation of oligonucleotide therapies with the aim of reworking the therapy of extreme neuromuscular and neurological ailments. PepGen’s Enhanced Supply Oligonucleotide (EDO) platform is based on over a decade of analysis and growth and leverages cell-penetrating peptides to enhance the uptake and exercise of conjugated oligonucleotide therapeutics. Utilizing these EDO peptides, we’re producing a pipeline of oligonucleotide therapeutic candidates designed to focus on the foundation trigger of significant ailments.
For extra data, please go to www.pepgen.com. Comply with PepGen on LinkedIn and X.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240820703812/en/
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Company Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Supply: PepGen Inc.